CATX

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at ASCO-GI 2026Nine patients experienced deepening of response since the ESMO presentation [212Pb]VMT-α-NET continues to be well-tolerated Initial efficacy data from additional 23 patients in Cohort 2 an

DEFA14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

DEF 14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside ChatDate: Tuesday, April 14, 2026Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s onlyDate: Thursday, April 16, 2026Location: Boston, MA About Perspective Therapeutics, Inc.

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clini

10-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026Clinical updates for all three clinical programs are expected to be submitted f

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /CNW/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That pipeline depth extends to radiopharmaceuticals, cell therapies, and device-based platforms now generating survival data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ:ONCY), Novocure (NASDAQ:NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ:IBRX), and Nuvation Bio Inc. (N

SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and other offering expe

FWP - Perspective Therapeutics, Inc. (0000728387) (Subject)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)